Policy Indications: How Materials Science Helps Contain Contain Covid-19 Spread  |  National Edu News: IIT Hyderabad and PharmCADD signed a pact for the co-development of new drugs   |  Teacher Insights: Be Game  |  Health Monitor: Understanding ‘Haemorrhage'  |  National Edu News: Pallikkutam GlobalConnect#3 on 'Innovative Tools for Effective Teaching'  |  Expert Counsel: The Nine Dash Line  |  National Edu News: Astronomers Find One Group of Appearing and Disappearing Stars  |  Teacher Insights: Bird Book for Children to Love Nature  |  International Edu News: New Model to Fight Social Media Deep Fakes  |  Teacher Insights: Universal Lunch Makes Students Healthier  |  Teacher Insights: Physical Activity Boosts Self Regulation  |  Parent Interventions: Anti-Inflammatory Foods Reduce Blood Fats  |  Parent Interventions: New Technique to Treat ADHD  |  Parent Interventions: Reduce Lab Tests in NICU Patients  |  Parent Interventions: Switch Off  |  
May 19, 2021 Wednesday 12:39:32 PM IST

Govt Supports Augmentation of Manufacturing Capacity for COVAXIN production

Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines. This is being implemented by the Department of Biotechnology, Govt. of India at Biotechnology Industry Research Assistance Council (BIRAC), New Delhi. To augment the capacity of Indigenous production of Covaxin under the Mission, theDepartment of Biotechnology, Government of India in April 2021 provided financial support as Grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach more than 10 crore doses per month by September 2021. As a part of this augmentation plan, the capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufacturers are being upgraded with the required infrastructure and technology. Financial support is being provided as a grant from GoI to the tune of approx. Rs 65 Cr to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.

The following three public sector companies are also being supported to increase the capacity of vaccine production. 1. Haffkine Biopharmaceutical Corporation Ltd, Mumbai-a State PSE under State Govt of Maharashtra. Financial support of Rs. 65 crores as a grant from GoI is being provided for this facility to make it ready for manufacturing. The facility will have a capacity of 20 million doses per month, once functional. 2. Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board is being provided a grant of Rs. 60 crores and 3. Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr a CPSE under the Department of Biotechnology, Government of India is being supported with a grant of Rs. 30 crores to prepare their facility to provide 10-15 million doses per month. Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt. of Gujarat along with Hester Biosciences and OmniBRx has also firmed up its discussions with Bharat Biotech to scale up the COVAXIN technology and to produce a minimum of 20 million doses per month. The technology transfer agreement has been finalized with all manufacturers.

Comments